BioPharma Credit PLC

31 JULY 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

STATEMENT RE REATA PHARMACEUTICALS

Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released Friday 28 July by Biogen Inc. ("Biogen") regarding the definitive agreement pursuant to which Biogen will acquire Reata Pharmaceuticals Inc. ("Reata") for an enterprise value of approximately US$7.3 billion (the "Transaction"). Biogen and Reata currently anticipate that the Transaction will close in the fourth quarter of 2023. 

The Company announced on 11 May 2023 an investment in a senior secured loan to Reata of up to US$137.5 million in up to four tranches. As of today, the Company had funded the first two tranches representing a US$62.5 million investment. The loan is expected to be prepaid upon the closing of the Transaction. Pursuant to the senior secured loan agreement, in connection with the Transaction and the repayment of outstanding principal, the Company is expected to receive a make-whole payment for the remainder of the two-year make-whole period along with a prepayment premium of 3%, in each case with respect to the principal repaid. For illustrative purposes, if the Transaction were to close on 30 September 2023, the Company would be expected to receive approximately US$15.5 million in prepayment and make-whole fees.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509